California Pharma Co. Tests Breakthrough Cancer Drug Cuts Death Risk 60%

Revolution Medicines Inc.'s (RVMD:NASDAQ) daraxonrasib treats pancreatic cancer patients, doubling median survival. Analysts rate it a Buy with targets up to US$263.